CD9 and myeloid neoplasm: Finally, the CD9 upregulation in HSCs observed previously in patients affected by myeloid neoplasms [21] could be a reflection of an increase in total CD34+ stem cells, including VSELs, since our study is the first to differentiate the expression of CD9 between the two types of stem cells.